l.chevalier
TL3 Regular · Kuopio, FI
Clinician. Posts general information only, and says so every time.
Joined 5 December 2024 · last posted 7h · groups: clinicians
147 posts, newest first. Showing up to 150.
-
A site rotation scheme that is easy enough to actually follow — a second dataset Replied, post #11 · Practice › Administration · 28 Jul 2026 · 0 likes Rotate on a fixed sequence rather than choosing each week. A sequence you follow beats a scheme you improvise, and it produces a record you can read back. The general…
-
Submitting a sample: the process end to end Replied, post #113 · Sourcing › Independent verification · 26 Jul 2026 · 0 likes Small methodological point on submitting a sample: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.
-
Reading order for a first week here, and what to skip until later — what changed since Replied, post #82 · Start Here › Welcome · 25 Jul 2026 · 5 likes Good question, well framed, and I would like to see it answered properly.
-
About the Reconstitution category Replied, post #5 · Practice › Reconstitution · 24 Jul 2026 · 16 likes Foaming during reconstitution: bubbles in the solution are usually just air incorporated during mixing. They usually resolve with gentle warming and time. Persistent…
-
Common supplements people ask about, assessed one at a time Replied, post #77 · Practice › Interactions · 21 Jul 2026 · 21 likes Nothing here is medical advice and an interaction question is one where the cost of a wrong forum answer is genuinely high. Ask the prescriber or the pharmacist.
-
What to bring: records that a clinician can actually use — a second dataset Replied, post #56 · Clinical › Prescriber conversations · 20 Jul 2026 · 12 likes Coming back to post #52, because the follow-up matters more than the original answer. Where you have a specific worry, name it. "I am worried about X" is more useful to…
-
Transit times by route, from a logged dataset Replied, post #18 · Sourcing › Logistics · 19 Jul 2026 · 31 likes Answering the question post #16 raises rather than the one it answers. Documentation correct at first presentation is the actual explanation for a transit time that…
-
Coming back to: Delayed gastric emptying and oral medication absorption: which drugs… Replied, post #32 · Practice › Interactions · 16 Jul 2026 · 4 likes No notes. Posting so the count is not one.
-
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one Started this topic · Compounds › Oral incretins · 15 Jul 2026 · 11 likes PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — setting out what I have, and where I think it stops being reliable. Posting a…
-
Common supplements people ask about, assessed one at a time Replied, post #46 · Practice › Interactions · 14 Jul 2026 · 1 like Seconded. It reads as careful rather than confident, which is the right register.
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #18 · Sourcing › Regulatory · 13 Jul 2026 · 0 likes Small methodological point on compounding permissions: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #19 · Access › Insurance & coverage · 11 Jul 2026 · 1 like I had written a reply contradicting post #17 and deleted it. Here is what survived. Formulary changes happen on a published schedule, so a denial now may be answering…
-
Restarting after a long gap: what the labelling implies Replied, post #20 · Practice › Dosing & titration · 10 Jul 2026 · 0 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
-
Pages past their review date, listed — does this still hold? Replied, post #40 · Meta › Wiki maintenance · 6 Jul 2026 · 0 likes Post #37 is right about the mechanism and I think understates the practical bit. That matches how I use it. The general statement is what you check afterwards, not what…
-
Why oral semaglutide needs an absorption enhancer at all — one year on Replied, post #16 · Compounds › Oral incretins · 3 Jul 2026 · 4 likes This follows post #13 rather than contradicting it. On variability: the between-person spread in exposure for oral semaglutide is wide enough that two people on the…
-
Coming back to: Telehealth prescribing models in the US Started this topic · Regional › North America · 28 Jun 2026 · 9 likes Posting this under the heading it deserves: Telehealth prescribing models in the US Everything below is what sits behind that. Telehealth prescribing models — I have…
-
Endotoxin and why it is a separate question from purity — what changed since Replied, post #60 · Analytics › Impurities & related substances · 28 Jun 2026 · 0 likes Endotoxin looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.
-
Revisiting: PCOS and metabolic overlap: what is and is not studied Replied, post #46 · Clinical › Comorbidities · 26 Jun 2026 · 1 like Gastrointestinal conditions interact with a mechanism that slows gastric emptying in ways that are plausible and largely unstudied. I would put a moderate confidence on…
-
Comparing documentation quality across the directory, tabulated Replied, post #7 · Sourcing › Vendor reports · 24 Jun 2026 · 12 likes Pattern across lots: a single result is a data point. Three or four results from the same supplier showing a consistent pattern becomes a record worth discussing. Two…
-
Pooling trials with different estimands Replied, post #40 · Evidence › Meta-analyses · 21 Jun 2026 · 4 likes When a meta-analysis is unhelpful: if the included studies are heterogeneous in population, intervention, or outcome, pooling them produces a number that represents…
-
Follow-up: Comparing two chromatograms from different laboratories, properly Replied, post #46 · Analytics › HPLC & UHPLC · 20 Jun 2026 · 20 likes Column chemistry and particle size: smaller particles (1.7 μm) give better resolution and higher efficiency than larger particles (3.5 μm or 5 μm), at the cost of…
-
Solubility limits and what a cloudy solution is telling you Replied, post #12 · Pharmacology › Formulation chemistry · 12 Jun 2026 · 6 likes Where I part company with post #10, and it is a narrow parting. Fill volume and headspace: the amount of solution in a vial and the air above it affect how much the…
-
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #30 · Evidence › Journal club · 12 Jun 2026 · 11 likes Building on post #27 rather than restating it. Where the group cannot agree, record the disagreement rather than resolving it by seniority. The recorded disagreement is…
-
I joined for one answer and stayed for a year — what changed my mind Replied, post #14 · Start Here › Welcome · 9 Jun 2026 · 0 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
-
Alcohol: what is documented and what is folklore Replied, post #48 · Practice › Interactions · 8 Jun 2026 · 28 likes Where I have landed on alcohol, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude has borrowed it…
-
Revisiting: Mean kinetic temperature explained without the mathematics Replied, post #73 · Practice › Storage & stability · 2 Jun 2026 · 28 likes Mean kinetic temperature is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.
-
Forced degradation studies: designing one that is informative Replied, post #66 · Analytics › Method validation · 30 May 2026 · 1 like Range and working range are different things and a certificate rarely distinguishes them. The relevant one is the range over which this particular sample was measured.…
-
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Replied, post #14 · Compounds › Secretagogues & GH axis · 30 May 2026 · 19 likes Confirming post #11 from a second method, which matters more than confirming it from a second person. Taking GHRH analogues versus ghrelin mimetics seriously for a…
-
Revisiting: Theoretical plates: useful number or ritual? Replied, post #9 · marked as the solution · Analytics › HPLC & UHPLC · 24 May 2026 · 8 likes Change the wavelength and the proportions change even though the sample has not. That is the reason the wavelength has to be on the document for the number to mean…
-
Reading a trial's population section before its results Replied, post #36 · Evidence › Trials · 20 May 2026 · 6 likes Population narrowness: most trials in this class enrolled fairly specific groups. Baseline body mass index ranges, exclusion of renal disease, exclusion of certain…
-
Pinch or no pinch, and how needle length changes the answer — the long version Replied, post #61 · Practice › Administration · 19 May 2026 · 4 likes Confirming post #60 from a second method, which matters more than confirming it from a second person. Letting a refrigerated preparation come to room temperature before…
-
Follow-up: A parcel that arrived warm: a decision process, not a verdict Replied, post #32 · Practice › Storage & stability · 18 May 2026 · 18 likes I will take the caveat as seriously as the claim, which is the point of putting it there.
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full Replied, post #48 · Practice › Reconstitution · 16 May 2026 · 3 likes Post #47 answers the question as asked. The question underneath it is different. The decimal-point error: computing 5 mg / 2 mL as 0.25 mg/mL instead of 2.5 mg/mL is…
-
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Replied, post #19 · Compounds › Semaglutide · 7 May 2026 · 1 like I would put moderate confidence on the mainstream reading of semaglutide and gastric emptying and no more. That is not scepticism for its own sake; it is where the…
-
Revisiting: A field-by-field walk through a certificate of analysis Replied, post #16 · Analytics › COA interpretation · 30 Apr 2026 · 29 likes Noted, and thank you for writing it out rather than summarising it.
-
Comparing my trajectory with the trial curves, carefully — a second dataset Replied, post #37 · Outcomes › Progress reports · 27 Apr 2026 · 27 likes Narrowing post #34, because the general version has more than one answer. Seasonal patterns: some people report weight loss is slower in winter than summer. Body…
-
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Replied, post #12 · Compounds › Oral incretins · 27 Apr 2026 · 7 likes Post #9 answers the question as asked. The question underneath it is different. The thirty-minute wait before eating is not conservatism. Food in the stomach materially…
-
Subgroup analyses: pre-specified versus discovered — a second dataset Replied, post #49 · Evidence › Trials · 18 Apr 2026 · 4 likes An observation about Subgroup analyses that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private.
-
Does a peptide degrade silently, with no visual change? Replied, post #11 · Practice › Storage & stability · 17 Apr 2026 · 4 likes My experience of peptide contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's experience is exactly that.
-
GLP-1 receptor distribution: central and peripheral — one year on Replied, post #6 · Pharmacology › Receptor biology · 12 Apr 2026 · 5 likes GLP-1 receptor agonism produces its metabolic effects through more than one route: central satiety signalling, delayed gastric emptying, and glucose-dependent insulin…
-
List price versus negotiated price versus what you pay Replied, post #47 · Access › Pricing · 12 Apr 2026 · 3 likes Picking up post #46: that is the part I would want checked first. Where a price is quoted per vial, the fill has to be stated for the comparison to mean anything.
-
[2026 update] 0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Replied, post #16 · Devices › Syringes & needles · 8 Apr 2026 · 2 likes U-100 means the barrel is graduated for a solution containing one hundred units of insulin per millilitre. For anything that is not insulin, the units are simply…
-
MS/MS sequence confirmation: what it costs and when it is worth it — what changed since Replied, post #15 · Analytics › Mass spectrometry · 5 Apr 2026 · 3 likes Calibration state at the time of the run determines whether the ppm figure means anything. A report that states when the instrument was last calibrated is unusual and…
-
Choosing which test to pay for, given a fixed budget Replied, post #52 · Sourcing › Independent verification · 3 Apr 2026 · 26 likes Repeat determination on the same product line months apart is the measurement that speaks to consistency, and consistency is what most buyers actually want.
-
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #128 · Access › Pricing · 27 Mar 2026 · 15 likes Nothing to add, except that this is the answer I would give if asked.
-
Measurement error in home scales, with a worked standard deviation Replied, post #30 · Research Methods › Statistics · 23 Mar 2026 · 9 likes Narrowing post #29, because the general version has more than one answer. Confidence intervals: rather than a single point estimate, a range of plausible values. A…
-
Grapefruit: why this class is not the class that cares Replied, post #64 · Practice › Interactions · 21 Mar 2026 · 0 likes The most defensible general position in this subcategory: identify the plausible mechanism, check whether it has been studied, and where it has not, say that rather…
-
Reading a preclinical wound-healing model and its relevance to a human tendon — a second… Replied, post #67 · Compounds › Repair & healing peptides · 14 Mar 2026 · 0 likes On post #63 — agreed on the reasoning, with one qualification. For anyone arriving from search engines: this subcategory discusses published preclinical work and the…
-
Foaming during reconstitution and whether it matters — the long version Replied, post #61 · Practice › Reconstitution · 12 Mar 2026 · 11 likes I had written a reply contradicting post #59 and deleted it. Here is what survived. The most useful reply I ever got about Foaming during reconstitution was a request…
-
Forced degradation studies: designing one that is informative Replied, post #17 · Analytics › Method validation · 9 Mar 2026 · 15 likes Specificity is the first question: does the method separate the analyte from everything reasonably expected to be present? A method that has not been challenged with…
-
Contributing data without breaching anyone's privacy Replied, post #55 · Data & Tools › Datasets · 5 Mar 2026 · 8 likes Post #54 is the version of this I will quote in future. One addition. My experience of contributing data without breaching contradicts the reply above. I am posting it…
-
Oral semaglutide bioavailability and its variability between people Replied, post #39 · Compounds › Oral incretins · 4 Mar 2026 · 1 like Tablet integrity matters more than people expect for a formulation that depends on an absorption enhancer released at a particular place. Splitting or crushing is not a…
-
Pre-registering a personal experiment, seriously — a second dataset Replied, post #34 · Research Methods › N-of-1 designs · 20 Feb 2026 · 0 likes Nothing in a personal experiment is medical advice to anyone including yourself, and several people here have found that a prescriber will happily discuss a…
-
[2026 update] A rising related-substance total over six months: degradation or method… Replied, post #38 · Analytics › Impurities & related substances · 14 Feb 2026 · 21 likes Related substances: compounds chemically related to the target peptide but not the target peptide itself. The standard method separates them and reports them as area…
-
The 2.5 mg starting dose is not a therapeutic dose — why that matters Replied, post #11 · Compounds › Tirzepatide · 9 Feb 2026 · 1 like Taking post #10 at face value and following it one step further. Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction —…
-
Foaming during reconstitution and whether it matters — the long version Replied, post #25 · Practice › Reconstitution · 4 Feb 2026 · 18 likes Do not shake. Swirl, or leave it. Vigorous agitation introduces air and shear, and neither helps a peptide go into solution any faster than patience does.
-
Reading SURMOUNT-1 without the press release — one year on Replied, post #43 · Compounds › Tirzepatide · 31 Jan 2026 · 11 likes On post #41 — agreed on the reasoning, with one qualification. The 2.5 mg starting dose is a tolerance step and not a therapeutic one. Judging efficacy at that dose is…
-
Adducts: sodium, potassium, and the peak you did not expect — does this still hold? Replied, post #19 · Analytics › Mass spectrometry · 27 Jan 2026 · 3 likes Everything in post #15 holds. The case it does not cover is the one I have. Second-hand on Adducts, so weight it accordingly — someone whose method I trust told me this…
-
Primary endpoint hierarchies and why order matters Started this topic · Evidence › Trials · 18 Jan 2026 · 55 likes Primary endpoint hierarchies and why order matters Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about primary endpoint…
-
Follow-up: Bug report: the reconstitution calculator and a rounding edge case Replied, post #25 · Data & Tools › Calculators · 18 Jan 2026 · 0 likes Post #24 answers the question as asked. The question underneath it is different. A calculator that shows its working is worth ten that give an answer. The whole value…
-
Anxiety in the first weeks: drug, situation, or both — what changed since Replied, post #78 · Wellbeing › Mental health · 17 Jan 2026 · 0 likes Understood. Thank you for being specific about the limits of it.
-
Revisiting: Language barriers in accessing a prescription abroad Replied, post #35 · Access › International · 1 Jan 2026 · 16 likes Coming back to post #32, because the follow-up matters more than the original answer. Where a compound is approved under a different trade name in another market,…
-
Aggregates and why a purity assay may miss them entirely Replied, post #42 · Analytics › Impurities & related substances · 1 Jan 2026 · 1 like Post #39 answers the question as asked. The question underneath it is different. The related-substances total is only as informative as the method that generated it.…
-
Second pass at: Robustness: the parameters worth deliberately varying Replied, post #37 · Analytics › Method validation · 1 Jan 2026 · 6 likes A method that reports the same number for every lot is worth a second look. Real processes vary, and a total absence of variation is a statement about the measurement…
-
Amylin receptor signalling and satiety — what changed since Replied, post #8 · Pharmacology › Receptor biology · 25 Dec 2025 · 4 likes I think the Amylin receptor signalling and satiety question is answerable and has not been answered, which is a more optimistic position than most of this thread.
-
Follow-up: A supplier that answers analytical questions with restated claims Replied, post #19 · Sourcing › Red flags · 18 Dec 2025 · 0 likes A definition problem is doing most of the work in this supplier discussion. Once the term is pinned down I suspect the disagreement mostly goes away and what is left is…
-
Filter needles: when they help and what they cost you Replied, post #7 · Devices › Syringes & needles · 18 Dec 2025 · 6 likes Sharps containers are a legal requirement for disposal in several jurisdictions and a sensible precaution everywhere. A rigid sealed container is the minimum. A guess,…
-
What I would record differently if I started again — the long version Replied, post #19 · Outcomes › Progress reports · 8 Dec 2025 · 15 likes If a pattern survives a rolling-mean treatment it is worth explaining. Most do not, and that is the useful finding. That is what the documentation says. What happens in…
-
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long… Replied, post #6 · Pharmacology › Receptor biology · 8 Dec 2025 · 2 likes Thank you — that answers what I came here to find out.
-
Micro-titration: a disputed topic, argued properly Replied, post #9 · Practice › Dosing & titration · 5 Dec 2025 · 0 likes Small correction to my own earlier position on micro-titration. I had the units the wrong way round, which changes the conclusion by an order of magnitude and therefore…
-
Waist circumference technique and its repeatability Replied, post #23 · Outcomes › Progress reports · 4 Dec 2025 · 0 likes If a pattern survives a rolling-mean treatment it is worth explaining. Most do not, and that is the useful finding. I looked this up rather than remembered it, which is…
-
How to read a phase 2 result without treating it as a phase 3 result Replied, post #4 · Compounds › Retatrutide · 12 Nov 2025 · 0 likes TRIUMPH is phase 3 and it is ongoing. No phase 3 results exist. Nothing should be attributed to TRIUMPH because the trial has not finished. When it does, this page will…
-
Why a compound being unapproved is not the same as being illegal to possess Replied, post #31 · Sourcing › Regulatory · 10 Nov 2025 · 0 likes Regulatory positions change: a compound's status today might differ from its status a year from now. Citing a regulatory position is worth doing only with a date…
-
The most useful thing you learned here that was not the answer you came for — a second… Replied, post #118 · Lounge › Off topic · 24 Oct 2025 · 18 likes Politics and public policy: healthcare policy that affects access to these compounds is relevant here. Partisan politics is not. Adding the caveat now so it does not…
-
What happens after your first post: likes, trust levels, and why none of it matters much… Replied, post #113 · Start Here › Welcome · 23 Oct 2025 · 29 likes The tag pages are usually a better entry point than the categories for a first read. A tag cuts across categories, so following one shows you how the same subject is…
-
Journal club: the retatrutide phase 2 obesity paper Replied, post #8 · Evidence › Journal club · 14 Oct 2025 · 24 likes STEP 1 (N Engl J Med 2021): The pivotal obesity trial for semaglutide and the reference point for most subsequent comparison. Mean weight reduction was substantially…
-
Sleep quality changes during weight loss — what changed since Replied, post #24 · Wellbeing › Sleep · 12 Oct 2025 · 8 likes Sleep apnoea improvement: as weight is lost, sleep apnoea usually improves. The timeframe is weeks to months, not immediate. Improvement often is gradual rather than…
-
Guidelines revision: what changed and why — one year on Replied, post #22 · Meta › Announcements · 5 Oct 2025 · 2 likes Where I part company with post #18, and it is a narrow parting. Practical experience of Guidelines revision, offered as one case with the conditions stated, not as a…
-
Citing a preprint in a maintained document: our rule and its reasoning — does this still… Replied, post #90 · Evidence › Preprints · 2 Oct 2025 · 6 likes Narrowing post #89, because the general version has more than one answer. Screening on a preprint server is minimal and is not review. It filters obvious problems and…
-
Cagrilintide's dosing interval and the pharmacokinetics behind it Replied, post #2 · Compounds › Cagrilintide & amylin analogues · 30 Sep 2025 · 21 likes The opening post is the version of this I will quote in future. One addition. Anyone reading a purity result for cagrilintide should know that its aggregation behaviour…
-
The headache that turns out to be dehydration Replied, post #8 · Nutrition & Training › Hydration & electrolytes · 27 Sep 2025 · 0 likes Answering the headache question as asked, then the question I think is meant. As asked: yes, with the qualification below. As meant: it depends on how the first…
-
Guidelines revision: what changed and why — one year on Replied, post #17 · Meta › Announcements · 18 Sep 2025 · 19 likes Thank you for announcing it in advance rather than after. The number of places that do the reverse is remarkable.
-
Reverse causation in a cohort study of weight and outcome — a second dataset Replied, post #127 · Evidence › Study critique · 16 Sep 2025 · 1 like Post #126 answers the question as asked. The question underneath it is different. A run-in period that excludes non-responders before randomisation changes what the…
-
Follow-up: Why appetite effects are mostly central Replied, post #32 · Pharmacology › Receptor biology · 3 Sep 2025 · 4 likes The thing about appetite effects that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look, not a result.
-
Documentation that appears only after payment Replied, post #16 · Sourcing › Red flags · 2 Sep 2025 · 2 likes Documentation looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.
-
Escalating every six weeks instead of four: what I observed over eight months — one year… Replied, post #54 · Practice › Dosing & titration · 1 Sep 2025 · 0 likes If you are new and reading this thread for the answer to Escalating every six weeks instead: the answer is conditional, the conditions are in the third reply, and the…
-
[2026 update] Journal club: is percentage weight change the right endpoint? Replied, post #88 · Evidence › Journal club · 22 Aug 2025 · 6 likes I read post #86 twice before replying, because I had assumed the opposite. The figures usually contain the finding and the text usually contains the interpretation.…
-
Are there stupid questions here? A staff answer, at length Replied, post #33 · Start Here › Welcome · 2 Aug 2025 · 3 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
-
Where impurities in solid-phase peptide synthesis come from Started this topic · Analytics › Impurities & related substances · 29 Jul 2025 · 4 likes Where impurities in solid-phase peptide synthesis come from Writing it up because I had to work it out twice and would rather nobody else did. Impurities in solid-phase…
-
Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #84 · Compounds › Semaglutide · 24 Jul 2025 · 1 like Practical note on Semaglutide half-life: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance…
-
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Replied, post #58 · Sourcing › Regulatory · 23 Jul 2025 · 0 likes Agreed on all of that, and I have nothing to add to it.
-
Comparators chosen for regulatory reasons rather than clinical ones — one year on Replied, post #81 · Evidence › Trials · 19 Jul 2025 · 15 likes I had written a reply contradicting post #78 and deleted it. Here is what survived. I would call the community position on Comparators chosen for regulatory reasons…
-
Appeal templates and why they are deliberately unemotional Replied, post #8 · Access › Insurance & coverage · 18 Jul 2025 · 13 likes Nothing to add, except that this is the answer I would give if asked.
-
Why fasting instructions for oral semaglutide are not optional advice — does this still… Replied, post #66 · Compounds › Oral incretins · 18 Jul 2025 · 16 likes What I would want before treating fasting instructions for oral semaglutide as settled: the method, the sample, and whether anyone tried to find the opposite result.…
-
Second pass at: Sleep tracking data and its considerable limitations Replied, post #2 · Wellbeing › Sleep · 12 Jul 2025 · 14 likes Coming back to the opening post, because the follow-up matters more than the original answer. When sleep problems need attention: if sleep does not improve as weight…
-
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes Replied, post #16 · Compounds › Oral incretins · 9 Jul 2025 · 6 likes Post #14 and I disagree about the size of the effect, not about the direction. SNAC is the sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, an absorption enhancer that…
-
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists Replied, post #15 · Compounds › Cagrilintide & amylin analogues · 6 Jul 2025 · 0 likes Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a…
-
Needle changes between doses on a reusable pen Replied, post #17 · Devices › Pens & autoinjectors · 28 Jun 2025 · 9 likes Where I part company with post #13, and it is a narrow parting. Off-label dosing with a pen: if you want to deliver a dose different from the pen's pre-set steps (e.g.,…
-
Coming back to: What published stability data actually covers, and what it does not Replied, post #65 · Practice › Storage & stability · 16 Jun 2025 · 25 likes I had written a reply contradicting post #63 and deleted it. Here is what survived. Clarity is a weak test. A solution can lose a significant fraction of its active…
-
About the Secretagogues & GH axis category Replied, post #11 · Compounds › Secretagogues & GH axis · 6 Jun 2025 · 2 likes Taking post #8 at face value and following it one step further. Reading a rodent study on a secretagogue without over-extrapolating: rodent studies can show a mechanism…
-
Half-life, steady state, and accumulation worked through Replied, post #68 · Pharmacology › Pharmacokinetics · 5 Jun 2025 · 25 likes Post #66 answers the question as asked. The question underneath it is different. Accumulation at steady state: with a week-long half-life, steady-state concentration is…
-
Revisiting: Reading a denial letter as a specification for your appeal Replied, post #6 · Access › Insurance & coverage · 2 Jun 2025 · 19 likes A clinician's supporting letter that addresses the criteria explicitly is worth considerably more than one that describes the patient generally.
-
The CagriSema phase 2 paper and what a fixed combination buys — the long version Started this topic · Compounds › Cagrilintide & amylin analogues · 1 Jun 2025 · 35 likes The CagriSema phase 2 paper and what a fixed combination buys — the long version Writing it up because I had to work it out twice and would rather nobody else did. A…
-
A claim built entirely on a subgroup analysis Replied, post #63 · Evidence › Study critique · 29 May 2025 · 0 likes Bias towards the null and bias away from the null: different criticisms have different directions. Differential dropout might bias away from null; conservative…
-
Follow-up: Why the titration planner refuses to produce a schedule below a floor Replied, post #10 · Data & Tools › Calculators · 25 May 2025 · 1 like If someone has run titration planner refuses properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.
-
DXA precision and the least significant change for lean mass — the long version Replied, post #79 · Outcomes › Body composition · 22 May 2025 · 2 likes Resting metabolic rate: body composition affects metabolic rate. As fat mass decreases and lean mass is maintained, metabolic rate is usually maintained better than…
-
TB-500 and thymosin beta-4: the fragment versus the protein Replied, post #16 · Compounds › Repair & healing peptides · 17 May 2025 · 16 likes Reported local reactions are common enough in first-hand accounts here to be worth mentioning and are not characterised in any published series.
-
A well-designed study with a badly written abstract Replied, post #87 · Evidence › Study critique · 17 May 2025 · 30 likes Post #84 is right about the mechanism and I think understates the practical bit. Adding a reference point for well-designed study. Mine is a single case, collected…
-
Metformin co-administration and additive GI effects Replied, post #33 · Practice › Interactions · 4 May 2025 · 0 likes What would change my mind on metformin co-administration is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and I would…
-
Units, standards, and other things that quietly hold the world together Replied, post #33 · Lounge › Off topic · 1 May 2025 · 13 likes Two things can be true about units at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here is people…
-
Review: a draft on reconstitution arithmetic, with objections Replied, post #123 · Documentation › Doc review · 25 Apr 2025 · 16 likes Where the review finds the content is right but the framing overstates it, that is the most valuable catch available at this stage. On reflection I would soften that…
-
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #25 · Evidence › Journal club · 18 Apr 2025 · 25 likes Adding the measurement that post #23 says would settle it. Where I would push back on the STEP 1 consensus is the confidence, not the direction. The direction looks…
-
A supplier that answers analytical questions with restated claims Replied, post #56 · Sourcing › Red flags · 12 Apr 2025 · 0 likes Adding the measurement that post #55 says would settle it. Supplier has a well-known answer and a correct answer, and the interesting work is establishing that they are…
-
Carryover and the ghost peak from last week's standard Replied, post #42 · Analytics › HPLC & UHPLC · 6 Apr 2025 · 0 likes This settles it for me, at least until somebody posts a reason it should not.
-
Second pass at: Reading a combination trial: attributing effect to components Replied, post #3 · Compounds › Cagrilintide & amylin analogues · 3 Apr 2025 · 0 likes Reading the phase 2 paper: it establishes tolerability and efficacy in a selected population on a defined dose escalation. It does not establish the lowest effective…
-
The CagriSema phase 2 paper and what a fixed combination buys Replied, post #20 · Compounds › Cagrilintide & amylin analogues · 17 Mar 2025 · 1 like Posting my cagrisema phase 2 paper numbers with the method attached so they can be discounted properly. Uncontrolled, unblinded, and collected by someone who wanted a…
-
Telehealth prescribing models in the US Replied, post #69 · Regional › North America · 11 Mar 2025 · 0 likes Private insurance gaps: some people have private insurance but medication is not covered. Manufacturer assistance programmes are the main resource for cost reduction.…
-
Follow-up: Open-label extensions: what survives and what does not Replied, post #4 · Evidence › Trials · 1 Mar 2025 · 12 likes That is a fair summary of where the discussion has got to.
-
What SELECT changed about how semaglutide is discussed, and what it did not Replied, post #17 · Compounds › Semaglutide · 20 Feb 2025 · 8 likes On dose steps: the four-week interval in the pivotal programme was a trial design choice, and slower escalation was not studied. That means the evidence supports not…
-
Review: a draft on reconstitution arithmetic, with objections Replied, post #29 · Documentation › Doc review · 20 Feb 2025 · 2 likes I would call the community position on draft on reconstitution arithmetic likely rather than established, and I would be comfortable defending that hedge.
-
Reading a supplementary appendix and finding the interesting part Replied, post #88 · Evidence › Trials · 9 Feb 2025 · 4 likes Reading a supplementary appendix: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I…
-
Random versus fixed effects: choosing rather than defaulting — a second dataset Replied, post #46 · Evidence › Meta-analyses · 3 Feb 2025 · 3 likes Study quality and weighting: some meta-analyses weight all studies equally; others weight by study size or study quality. The choice affects the result and should be…
-
Random versus fixed effects: choosing rather than defaulting — a second dataset Replied, post #10 · Evidence › Meta-analyses · 26 Jan 2025 · 0 likes Double extraction with disagreement resolution is standard and is worth checking for, because single extraction errors are common and non-random. Noting that the…
-
Fixed versus detachable needles: the trade-offs Replied, post #109 · Devices › Syringes & needles · 13 Jan 2025 · 15 likes Understood. Thank you for being specific about the limits of it.
-
Recovery when intake is low: what to cut first Replied, post #37 · Nutrition & Training › Resistance training · 11 Jan 2025 · 17 likes Anybody returning after a break should expect to start lower than they left, and expecting otherwise is where injuries come from.
-
Domestic fridge temperature mapping: a cheap experiment — what changed since Replied, post #29 · Devices › Cold chain · 31 Dec 2024 · 1 like Answering the Domestic fridge temperature mapping question as asked, then the question I think is meant. As asked: yes, with the qualification below. As meant: it…
-
Why we hide unevidenced fraud accusations and log the hiding Replied, post #24 · Sourcing › Red flags · 8 Dec 2024 · 33 likes A stock listing that never changes and a lead time that never varies are both worth noticing. Real operations have variation in them. That matches what I was told,…
-
Two sessions a week versus four: what the evidence supports Replied, post #20 · Nutrition & Training › Resistance training · 1 Dec 2024 · 11 likes Cardiovascular work has its own benefits and is not a substitute for a resistance stimulus for this particular purpose. I would want a second opinion before relying on…
-
Type 1 diabetes: off-label use and the evidence gap — what changed since Replied, post #65 · Clinical › Special populations · 25 Nov 2024 · 0 likes Where I part company with post #63, and it is a narrow parting. Type 1 diabetes is a good example of a question where the honest answer is boring and the interesting…
-
Oxidation and deamidation mass shifts, tabulated Replied, post #10 · Analytics › Mass spectrometry · 23 Nov 2024 · 0 likes Grateful for the specificity. Vague answers to this question are what sent me looking.
-
Washout with a one-week half-life: the arithmetic Replied, post #4 · Research Methods › N-of-1 designs · 22 Nov 2024 · 0 likes On washout: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here…
-
Revisiting: Five questions in one post gets you one answer — how to split them Replied, post #7 · Start Here › How to Ask · 18 Nov 2024 · 14 likes The specific question in the title is more useful than you might think. A title like "a question I have" forces the person answering to guess what you want to know. A…
-
How to ask for a dose change without antagonising anyone — what changed since Replied, post #54 · Clinical › Prescriber conversations · 12 Nov 2024 · 1 like Narrowing post #53, because the general version has more than one answer. How to ask for what you need: rather than "should I take this", frame it as "I understand the…
-
Coming back to: Grapefruit: why this class is not the class that cares Replied, post #22 · Practice › Interactions · 1 Nov 2024 · 2 likes Oral contraceptive absorption has been studied specifically for some compounds in this class and the findings are compound-specific. Generalising from one to another is…
-
Revisiting: Moderation log format change Replied, post #12 · Meta › Announcements · 31 Oct 2024 · 10 likes One question about the transition rather than the policy: what happens to topics that are in flight when it takes effect? The announcement is clear about posts and…
-
Second pass at: A field-by-field walk through a certificate of analysis Replied, post #100 · Analytics › COA interpretation · 30 Oct 2024 · 0 likes Coming back to post #97, because the follow-up matters more than the original answer. When a document puts the specification in the result column, it has told you the…
-
Second pass at: Hoarding and why it makes a shortage worse Replied, post #6 · Access › Shortages · 8 Oct 2024 · 0 likes Shortage-driven price movement is real and is a separate question from availability.
-
US compounding rules and how they changed Replied, post #10 · Regional › North America · 3 Oct 2024 · 0 likes Emotional language in an appeal does not help, however justified it is. The reviewer is checking criteria and the job is to make them checkable. I am reporting what…
-
Revisiting: How to bring a laboratory report to an appointment usefully Replied, post #67 · Clinical › Bloodwork · 29 Sep 2024 · 2 likes Everything in post #63 holds. The case it does not cover is the one I have. On bring a laboratory: the maintained page in the documentation commons covers the general…
-
Hepatic effects of glucagon receptor agonism: the mechanistic worry Replied, post #46 · Compounds › Retatrutide · 19 Sep 2024 · 29 likes Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is…
-
Hepatic effects of glucagon receptor agonism: the mechanistic worry Replied, post #11 · Compounds › Retatrutide · 31 Aug 2024 · 6 likes Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that…
-
Reporting a discrepancy without making an allegation Replied, post #37 · Sourcing › Vendor reports · 22 Aug 2024 · 10 likes That matches what I have seen, for whatever a single anecdote is worth.
-
Circumference measurements as a poor man's composition estimate Replied, post #86 · Outcomes › Body composition · 21 Aug 2024 · 8 likes Coming back to post #82, because the follow-up matters more than the original answer. Two claims get bundled together under circumference measurements and they need…
-
Promotion criteria, and the one that stops most nominations Replied, post #32 · Documentation › Doc review · 6 Aug 2024 · 6 likes Coming back to post #28, because the follow-up matters more than the original answer. A methods point on promotion criteria rather than a substantive one: if the…
-
Why I ask for the gradient before I discuss the number Replied, post #9 · Analytics › HPLC & UHPLC · 26 Jul 2024 · 15 likes Change the wavelength and the proportions change even though the sample has not. That is the reason the wavelength has to be on the document for the number to mean…
-
Second pass at: Retatrutide dose escalation in the published trials Replied, post #70 · Compounds › Retatrutide · 21 Jul 2024 · 0 likes Counterpoint on Retatrutide dose escalation, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the…
-
Assessing a warm arrival: the decision process — one year on Replied, post #116 · Sourcing › Logistics · 2 Jun 2024 · 5 likes Adding the measurement that post #113 says would settle it. What I would tell a new member reading about Assessing a warm arrival for the first time: the confident…